Cardio Diagnostics Whitepaper Highlights Gaps in Non-Obstructive Coronary Artery Disease Diagnosis
Found this article helpful?
Share it with your network and spread the knowledge!

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, has released a whitepaper examining the diagnostic challenges of non-obstructive coronary artery disease (NOCAD), a condition where patients experience coronary disease symptoms without significant blockages in major arteries. The report highlights limitations of invasive coronary angiography, which assesses anatomy rather than function, and brings attention to ischemia with no obstructive coronary arteries (INOCA), affecting an estimated 3 million to 4 million Americans. The whitepaper outlines clinical approaches to identify patients earlier, including the potential role of epigenetics-based testing in primary care, and examines NOCAD subgroups, diagnostic pathways, and opportunities to improve detection of coronary disease that conventional angiography may miss. Cardio Diagnostics also underscored its efforts to build clinical evidence for PrecisionCHD, its AI- and epigenetics-based blood test designed to aid in diagnosing coronary heart disease, including potential application in identifying INOCA patients whose symptoms remain unexplained by traditional testing. For full details, visit the company's press release at https://ibn.fm/N5RnS.
This development matters economically for Texas and the broader U.S. healthcare system. NOCAD and INOCA often go undiagnosed because standard angiography focuses on blockages, leaving many patients without clear explanations for their symptoms. Missed diagnoses can lead to repeated testing, unnecessary procedures, and delayed treatment, driving up costs and worsening outcomes. By targeting earlier detection with AI and epigenetics, Cardio Diagnostics aims to shift cardiovascular care toward more precise, accessible, and personalized solutions. The company's proprietary Integrated Genetic-Epigenetic Engine underpins its clinical tests, positioning it to become a leading medical technology company for prevention, detection, and treatment of cardiovascular disease. For investors and industry observers, the latest updates on CDIO are available in the company's newsroom at https://ibn.fm/CDIO.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For more information on BioMedWire's services, see its corporate communications solutions.
For Texas, the story underscores the state's growing role in health technology and life sciences communications. As companies like Cardio Diagnostics advance evidence for novel diagnostics, the economic impact could be significant: better detection may reduce costly late-stage interventions, improve workforce health, and attract further investment in Texas-based medtech and supporting services. The whitepaper's focus on primary care integration also signals a potential shift in how cardiovascular risk is assessed, with blood-based tools potentially complementing or reducing reliance on invasive procedures. While the clinical and commercial path requires further validation, the announcement positions Cardio Diagnostics at the intersection of AI, epigenetics, and preventive cardiology—a space with substantial implications for patients, providers, and payers alike.
